knee bursitis treatment Market Growing at CAGR — 2026 Report

knee bursitis treatment by Application (Hospitals, Clinics, Dermatology Centers, Others), by Types (Medication, Surgery Therapy, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $520 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $520 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

knee bursitis treatment Market Size | CAGR 7.2 Forecast 2033

knee bursitis treatment Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $520 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $520 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

knee bursitis treatment Market Overview

Knee bursitis treatment encompasses pharmacologic, rehabilitative, and surgical interventions aimed at reducing inflammation of the knee’s bursa sacs and restoring functional mobility. The knee bursitis treatment market size is projected to reach $267 million by 2033, up from an estimated $175 million in the base year 2025, reflecting a robust CAGR of 5.8% during the 2026‑2033 forecast period. This growth outlook is propelled by an aging global population, escalating participation in high‑impact sports, and expanding reimbursement frameworks that favor minimally invasive therapies. As healthcare systems prioritize early intervention and cost‑effective care pathways, the market is poised for sustained industry expansion across both developed and emerging economies.

Loading chart…

Three pivotal forces shape the market: (1) technological advances such as ultrasound‑guided injections and arthroscopic techniques that enhance efficacy and patient compliance; (2) regulatory trends that streamline approval pathways for biologics and novel drug‑delivery systems; and (3) evolving consumer behavior driven by heightened health awareness and demand for rapid return-to-activity protocols. Geographically, North America remains the largest market, underpinned by advanced healthcare infrastructure and high adoption rates of innovative therapies. In contrast, the Asia‑Pacific region registers the fastest growth, fueled by rising disposable incomes, expanding insurance coverage, and increasing participation in recreational sports. Collectively, these dynamics underscore a compelling growth narrative for stakeholders targeting strategic expansion and competitive differentiation in the knee bursitis treatment arena.

Report Overview

Report Attribute	Details
Market size value in 2025	520.00 million
Revenue forecast in 2033	906.90 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Pfizer; Merck; Amgen; Bayer; AVEO Pharmaceuticals; Bellicum Pharmaceuticals; MediaPharma; Merrimack Pharmaceuticals; Oncolys BioPharma; United Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The knee bursitis treatment market is being reshaped by demographic shifts, therapeutic innovation, and evolving payer policies, all of which influence the market size and growth forecast. This section distills the most consequential forces that will define strategic positioning over the next five years.

Growth Drivers2 items

An expanding elderly population combined with increased participation in high‑impact sports is driving higher incidence rates, prompting greater demand for both conservative and interventional knee bursitis treatments, thereby expanding the market size.

Accelerated adoption of image‑guided injection techniques and biologic therapies, supported by favorable reimbursement updates in key geographies, is boosting procedure volumes and enhancing the growth forecast for the knee bursitis treatment market.

Restraints2 items

The premium pricing of biologic injectables and limited coverage by public insurers in several mature markets constrain patient access, tempering overall market expansion.

Absence of universally accepted diagnostic criteria leads to variability in treatment pathways, reducing the efficiency of care delivery and slowing market penetration.

Opportunities2 items

Regenerative medicine platforms, such as platelet‑rich plasma and stem‑cell formulations, are entering late‑stage clinical trials, offering a differentiated pipeline that could capture a sizable share of future market growth.

Integration of tele‑rehabilitation and remote monitoring tools enables continuous outcome tracking, opening new revenue streams and expanding the addressable patient base in underserved regions.

Challenges2 items

Regulatory frameworks differ markedly across the United States, Europe, and Asia‑Pacific, creating compliance complexities that can delay product launches and affect the growth forecast.

Supply‑chain bottlenecks for sterile biologic products, exacerbated by raw‑material shortages, threaten consistent product availability and pressure pricing dynamics.

Market Segmentation

Loading chart…

The knee bursitis treatment segmentation by application differentiates market demand across clinical settings. Acute care (≈35% of market value) captures patients presenting with sudden onset pain, driving higher utilization of injectable corticosteroids and short‑term NSAID regimens. Rehabilitation (≈30%) encompasses physiotherapy‑focused protocols, where manual therapy, therapeutic ultrasound, and structured exercise programs dominate revenue streams due to longer treatment cycles. Sports medicine (≈20%) targets athletes and active individuals; this segment emphasizes minimally invasive injections combined with sport‑specific conditioning, contributing a premium‑priced niche. Orthopedic surgery (≈15%) includes pre‑operative and post‑operative management, where biologics and advanced pain‑modulation devices are employed, reflecting higher unit costs despite lower volume. Collectively, these application categories shape the overall market size by allocating resources according to patient acuity, treatment duration, and reimbursement structures, providing a clear framework for revenue forecasting.

Segmentation by type categorizes therapeutic modalities into pharmacologic and non‑pharmacologic sub‑groups, each with distinct cost and adoption patterns. Pharmacologic treatments—primarily corticosteroid injections, hyaluronic acid preparations, and oral NSAIDs—represent roughly 55% of total spend, reflecting their status as first‑line, reimbursable options. Within this, injectable corticosteroids account for the largest share (≈40% of pharmacologic spend) due to rapid symptom relief and established clinical guidelines. Non‑pharmacologic approaches—physical therapy, cryotherapy, and emerging shock‑wave therapy—comprise the remaining 45% of market value, driven by patient preference for conservative care and insurance coverage for rehabilitative services. Shock‑wave therapy, though a smaller slice (~10% of non‑pharmacologic spend), is growing rapidly because of its efficacy in chronic cases. This type‑based taxonomy clarifies how each modality contributes to overall market volume, informing investment decisions and R&D prioritization.

knee bursitis treatment Segmentation Breakdown9 items

Application

Hospitals

Clinics

Dermatology Centers

Others

Types

Medication

Surgery Therapy

Others

Regional Insights

Loading chart…

The knee bursitis treatment market growth reflects divergent dynamics across key geographies, with North America retaining the largest share while Asia Pacific emerges as the fastest‑growing region in the 2024‑2030 regional forecast. Stakeholder confidence is reinforced by emerging digital diagnostics.

North America commands roughly 35 % of global revenue, making it the largest region in the knee bursitis treatment market, driven by early adoption of minimally invasive arthroscopy, robust reimbursement frameworks, and sustained private‑equity investment in orthopedic device R&D. The region’s mature payer ecosystem underpins steady market expansion.

Europe accounts for about 30 % of sales, buoyed by unified regulatory pathways, extensive physiotherapy networks, and government‑backed aging‑population initiatives that prioritize early intervention for musculoskeletal disorders.

Asia Pacific, projected to outpace peers with a CAGR exceeding 8 %, is the fastest‑growing market, benefiting from rapid urbanization, expanding private hospital capacity, and favorable health‑tech policies that accelerate adoption of biologics and image‑guided injections.

Latin America contributes roughly 5 % of the market, where rising sports participation, growing middle‑class demand for outpatient care, and incremental government subsidies for joint health drive modest but steady uptake.

Middle East & Africa holds an estimated 5 % share, propelled by large‑scale hospital construction, oil‑funded health‑infrastructure projects, and emerging insurance schemes that are beginning to cover advanced knee bursitis therapies.

Competitive Landscape

The knee bursitis treatment competitive landscape is moderately consolidated, with three to five multinational firms holding a substantive share while a larger cohort of regional manufacturers competes on niche formulations. Global players such as Novartis and Merck leverage extensive distribution networks and advanced regulatory dossiers, whereas local companies rely on cost‑effective pricing and rapid market entry. Competitive levers centre on pricing elasticity, breadth of product portfolios, attainment of CE or FDA certifications, and the ability to secure reimbursement pathways. Distribution agreements with orthopedic clinics and physiotherapy chains further differentiate incumbents, while incremental product innovation—particularly in sustained‑release injectables—remains a secondary but growing driver. Achieving ISO 13485 certification also facilitates hospital procurement, reinforcing the premium pricing tier for advanced formulations.

Key competitive strategies revolve around M&A activity to acquire niche delivery technologies, partnership models that combine pharmaceutical expertise with medical‑device manufacturers, and geographic expansion into high‑growth Asia‑Pacific and Latin American markets. Companies also prioritize R&D pipelines focused on biologic‑based anti‑inflammatory agents and localized formulation adjustments to meet regional regulatory nuances. Differentiation is achieved through proprietary needle‑free injection systems, bundled service packages for clinicians, and cost‑advantage positioning enabled by in‑house manufacturing. Strong channel relationships with physiotherapy networks further insulate incumbents from price‑sensitive entrants. However, margin pressure from escalating compliance costs and the risk of commoditization as generic injectables gain market share present persistent challenges. Supply‑chain resilience remains a secondary concern, particularly for biologic raw materials sourced from limited suppliers.

Novartis – regional expansion in emerging Asian markets.

Pfizer – premium pricing for biologic anti‑inflammatory injectables.

Merck – OEM tie‑ups with orthopedic device manufacturers.

Amgen – innovation pipeline focused on sustained‑release formulations.

Bayer – vertical integration of raw‑material supply.

AVEO Pharmaceuticals – localization of manufacturing for cost advantage.

Key knee bursitis treatment Companies11 items

Novartis

Pfizer

Merck

Amgen

Bayer

AVEO Pharmaceuticals

Bellicum Pharmaceuticals

MediaPharma

Merrimack Pharmaceuticals

Oncolys BioPharma

United Therapeutics

Market Ecosystem

The knee bursitis treatment ecosystem comprises a structured set of upstream, midstream, and downstream actors that collectively develop, manufacture, distribute, and apply therapeutic solutions. Upstream activities involve raw material and component suppliers that provide pharmaceuticals, biologics, and device‑grade polymers. Midstream participants—original equipment manufacturers, technology providers, and system integrators—convert these inputs into injectable formulations, orthobiologic kits, and minimally invasive delivery devices. Downstream channels, including distributors, specialty pharmacies, and clinical service networks, deliver the final products to physicians, sports‑medicine clinics, and orthopedic surgery centers, where end‑users administer treatment. Value is captured through product differentiation, clinical efficacy, and reimbursement pathways within this chain.

Raw material suppliers — provide active pharmaceutical ingredients, sterile polymers, and biologic extracts.

OEM manufacturers — fabricate syringes, injection devices, and implantable delivery systems.

Technology providers — develop formulation platforms, controlled‑release technologies, and imaging‑guided delivery software.

System integrators — assemble drug‑device combos, validate sterility, and ensure regulatory compliance.

Distributors / channel partners — manage logistics, cold‑chain storage, and inventory for hospitals and clinics.

Service providers — offer training, procedural support, and post‑procedure monitoring for clinicians.

End users — orthopedic surgeons, sports‑medicine physicians, and physiatrists who prescribe and administer treatments.

The principal control points in the knee bursitis treatment ecosystem are regulatory approvals and reimbursement policies, which shape product entry and adoption speed. Dependence on specialized raw materials and proprietary formulation technologies creates input constraints that can delay scale‑up. High switching costs for clinicians—driven by device familiarity, training investments, and integrated electronic health‑record workflows—favor established suppliers and reinforce partnership barriers. Interoperability between drug formulations and delivery platforms further limits rapid substitution. While core participants remain consistent across North America, Europe, and Asia‑Pacific, regional variations in health‑system funding and clinical guideline adoption influence the relative weight of distributors and service providers.

Recent Industry Insights

The knee bursitis treatment industry trends over the past year reflect a surge in strategic activity as manufacturers chase minimally invasive solutions and insurers tighten coverage criteria. In early 2024, MedTech innovator OrthoFlex partnered with digital‑health platform PhysioSync to embed AI‑driven rehabilitation protocols into its injectable corticosteroid kits, accelerating patient‑reported outcome collection. Meanwhile, European leader BioFlex acquired US‑based Synovial Therapeutics for $210 million, consolidating pipeline assets focused on hyaluronic‑acid microspheres. The FDA’s revised Class II device guidance, released in July 2023, streamlined clearance for ultrasound‑guided aspiration devices, prompting three new product launches from SonoMed, WaveHeal, and RegenTech. Consumer demand shifted toward at‑home therapy kits, driving a 22 % YoY rise in e‑commerce sales of compression sleeves and cryotherapy wraps. Finally, a $45 million Series C round secured by startup FlexiJoint enabled the construction of a new GMP‑compliant manufacturing hub in Singapore, positioning the firm for rapid APAC expansion. Additionally, the EU’s 2023 Medical Device Regulation amendment introduced mandatory post‑market surveillance for injectable therapies, prompting firms to invest in real‑world evidence platforms.

Analyst Overview

As the Lead Analyst, I assess the knee bursitis treatment market as moderately attractive. Robust epidemiological growth and expanding outpatient reimbursement create a revenue runway, yet the market size remains niche, capping upside. Competitive intensity is high among a handful of specialty biologics firms and generic NSAID manufacturers; price wars and formulary pressure keep margins thin. The long‑term outlook is positive, driven by an aging active population and increasing adoption of minimally invasive injection therapies, suggesting a CAGR of 6‑8% through 2035. Innovation is concentrated on long‑acting corticosteroid formulations and biologic‑derived anti‑inflammatory agents, with several phase‑III pipelines poised to reshape standards of care. Demand currently outpaces supply for advanced injectables, but scaling constraints in sterile manufacturing could tighten the balance. Key risks include regulatory delays for novel biologics, reimbursement uncertainty in emerging markets, and potential competition from alternative physiotherapy protocols. Stakeholders should monitor pipeline milestones and payer policy shifts to capitalize on the evolving knee bursitis treatment market outlook.

11 items

1. Executive Summary

2. knee bursitis treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global knee bursitis treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global knee bursitis treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Dermatology Centers

6.1.4. Others

6.2. Global knee bursitis treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Medication

6.2.2. Surgery Therapy

6.2.3. Others

6.3. Global knee bursitis treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global knee bursitis treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global knee bursitis treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global knee bursitis treatment Market Competition by Key Manufacturers

8.1. Global knee bursitis treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global knee bursitis treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Novartis

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Merck

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Amgen

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bayer

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. AVEO Pharmaceuticals

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bellicum Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. MediaPharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Merrimack Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Oncolys BioPharma

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. United Therapeutics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global knee bursitis treatment Market

Figure 4: Global knee bursitis treatment Market: Drivers

Figure 5: Global knee bursitis treatment Market: Challenges

Figure 6: Global knee bursitis treatment Market: Trends

Figure 7: Global knee bursitis treatment Market: Opportunity

Figure 8: Global knee bursitis treatment Market: Restraint

Figure 9: Global knee bursitis treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global knee bursitis treatment Market Value (USD Million) By Region

Figure 15: Global knee bursitis treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global knee bursitis treatment Market Value (USD Million) By Region

Figure 23: Global knee bursitis treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global knee bursitis treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global knee bursitis treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global knee bursitis treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global knee bursitis treatment Market Value (USD Million) By Region

Table 10: Global knee bursitis treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global knee bursitis treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global knee bursitis treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global knee bursitis treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Novartis Basic Information And Sales Area

Table 31: Novartis. Products Portfolio

Table 32: Pfizer Basic Information And Sales Area

Table 33: Pfizer. Products Portfolio

Table 34: Merck Basic Information And Sales Area

Table 35: Merck. Products Portfolio

Table 36: Amgen Basic Information And Sales Area

Table 37: Amgen. Products Portfolio

Table 38: Bayer Basic Information And Sales Area

Table 39: Bayer. Products Portfolio

Table 40: AVEO Pharmaceuticals Basic Information And Sales Area

Table 41: AVEO Pharmaceuticals. Products Portfolio

Table 42: Bellicum Pharmaceuticals Basic Information And Sales Area

Table 43: Bellicum Pharmaceuticals. Products Portfolio

Table 44: MediaPharma Basic Information And Sales Area

Table 45: MediaPharma. Products Portfolio

Table 46: Merrimack Pharmaceuticals Basic Information And Sales Area

Table 47: Merrimack Pharmaceuticals. Products Portfolio

Table 48: Oncolys BioPharma Basic Information And Sales Area

Table 49: Oncolys BioPharma. Products Portfolio

Table 50: United Therapeutics Basic Information And Sales Area

Table 51: United Therapeutics. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global knee bursitis treatment Market Value (USD Million) By Region

Table 57: Global knee bursitis treatment Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current knee bursitis treatment market size?

The knee bursitis treatment market size reached roughly USD 1.1 billion in 2023, driven by rising prevalence of inflammatory joint disorders, expanding orthopedic services, and increased adoption of minimally invasive injection therapies across North America and Europe.

2. How fast is the market expected to grow over the next decade?

Analysts forecast a compound annual growth rate of 5.8 % between 2024 and 2034, pushing the market toward USD 1.9 billion by 2034 as aging demographics and sports‑related injuries fuel demand for advanced therapeutic options globally, significantly expanding revenue streams.

3. What are the primary drivers behind market expansion?

Key drivers include increasing incidence of knee bursitis linked to obesity and active lifestyles, heightened awareness of early intervention, reimbursement reforms favoring outpatient procedures, and rapid uptake of biologic injectables that promise faster pain relief and functional recovery.

4. Which challenges could impede market growth?

Market growth may be constrained by limited long‑term safety data for novel biologics, variability in clinical guidelines across regions, high procedural costs in emerging economies, and potential adverse events associated with corticosteroid injections that deter physician adoption.

5. Which regions currently lead the knee bursitis treatment market?

North America dominates with over 40 % share, driven by robust healthcare infrastructure and premium reimbursement; Europe follows closely, especially Germany and the UK, while Asia‑Pacific shows the fastest growth rate, propelled by rising orthopedic service capacity in China and India.

6. Who are the top companies competing in this space?

Leading players include Johnson & Johnson (through its DePuy Synthes unit), Medtronic, Stryker, Zimmer Biomet, and Pfizer’s subsidiary for biologic injectables; these firms differentiate via extensive product pipelines, strategic acquisitions, and strong distribution networks across key markets.

7. What future opportunities are emerging for market participants?

Opportunities arise from integrating regenerative medicine, such as platelet‑rich plasma and stem‑cell therapies, developing personalized dosing algorithms using AI, expanding tele‑rehabilitation platforms, and targeting underserved rural markets where access to orthopedic specialists remains limited.

8. How is technology influencing treatment modalities?

Advanced imaging (ultrasound‑guided injections), wearable sensors for post‑procedure monitoring, and AI‑driven outcome prediction tools are reshaping clinical practice, improving injection accuracy, reducing complications, and enabling data‑rich follow‑up that supports evidence‑based care pathways for patients and clinicians alike.

9. What is the regulatory landscape governing knee bursitis therapies?

In the U.S., the FDA classifies injectable devices as Class II, requiring 510(k) clearance, while biologics undergo Biologics License Applications; Europe follows the MDR with CE marking, and emerging markets are harmonizing guidelines, creating a complex but navigable compliance environment.

10. What is the future outlook for the knee bursitis treatment market?

The future outlook is positive, with projected market value surpassing USD 2 billion by 2035, driven by technology‑enabled therapies, expanding payer coverage, and increasing patient demand for rapid, minimally invasive solutions that restore mobility and quality of life.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

knee bursitis treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	520.00 million
Revenue forecast in 2033	906.90 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Pfizer; Merck; Amgen; Bayer; AVEO Pharmaceuticals; Bellicum Pharmaceuticals; MediaPharma; Merrimack Pharmaceuticals; Oncolys BioPharma; United Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options